First-line treatment with ribociclib and letrozole in advanced breast cancer: First interim data from US patients enrolled in the phase 3b CompLEEment-1 clinical trial

被引：0
|
作者：
Lu, J.
Shtivelband, M. I.
Mitri, Z.
Chap, L.
Purkayastha, D.
Sawhney, A. G.
Beck, J. T.
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] Ironwood Canc & Res Ctr, Chandler, AZ USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Highlands Oncol Grp, Fayetteville, AR USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-25
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    De Laurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Javier Salvador
    Jacot, William
    Dent, Susan
    Martin, Miguel
    Ring, Alistair
    Cottu, Paul
    Lu, Janice
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Zamagni, Claudio
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 689 - 699
  • [2] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    Michelino De Laurentiis
    Simona Borstnar
    Mario Campone
    Ellen Warner
    Javier Salvador Bofill
    William Jacot
    Susan Dent
    Miguel Martin
    Alistair Ring
    Paul Cottu
    Janice Lu
    Eva Ciruelos
    Hamdy A. Azim
    Sanjoy Chatterjee
    Katie Zhou
    Jiwen Wu
    Lakshmi Menon-Singh
    Claudio Zamagni
    Breast Cancer Research and Treatment, 2021, 189 : 689 - 699
  • [3] Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    Michelino De Laurentiis
    Simona Borstnar
    Mario Campone
    Ellen Warner
    Javier Salvador Bofill
    William Jacot
    Susan Dent
    Miguel Martin
    Alistair Ring
    Paul Cottu
    Janice Lu
    Eva Ciruelos
    Hamdy A. Azim
    Sanjoy Chatterjee
    Katie Zhou
    Jiwen Wu
    Lakshmi Menon-Singh
    Claudio Zamagni
    Breast Cancer Research and Treatment, 2022, 191 : 223 - 224
  • [4] Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results
    Salvador, J.
    Ciruelos, E. M.
    Jimenez-Rodriguez, B.
    De La Cruz, L.
    Villanueva Vazquez, R.
    De Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Quiroga, V.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos, B.
    Delgado Mingorance, I.
    Bellet Ezquerra, M.
    Martin, M.
    Martinez, N.
    Vicente, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 119 - +
  • [5] First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib plus letrozole HR+HER2-advanced breast cancer trial
    Ferrario, C.
    Warner, E.
    Califaretti, N.
    Joy, A. A.
    Chia, S.
    Wu, J.
    Zarate, J. P.
    Lakshmi, M.
    Perri, S. R.
    Haftchenary, S.
    Dent, S. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    De Laurentiis, Michelino
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)
    De Laurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Javier Salvador
    Jacot, William
    Dent, Susan
    Martin, Miguel
    Ring, Alistair
    Cottu, Paul
    Lu, Janice
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Zamagni, Claudio
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 223 - 224
  • [8] Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2-advanced breast cancer (ABC).
    DeLaurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Salvador
    Jacot, William
    Dent, Susan Faye
    Martin, Miguel
    Ring, Alistair E.
    Cottu, Paul H.
    Lu, Janice M.
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    Zamagni, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase 3b CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer: Final results from the UK cohort
    Tuthill, Mark
    Marwaha, Hardeep
    Hartmann, Christoph E. A.
    CANCER RESEARCH, 2021, 81 (04)
  • [10] A PLAIN-LANGUAGE SUMMARYOF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER
    Warner, Ellen
    De laurentiis, Michelino
    Martin, Miguel
    Cottu, Paul
    Lu, Janice
    Azim, Hamdy
    Aubel, Dawn
    Zhou, Katie
    Wu, Jiwen
    Menon, Lakshmi
    Zamagni, Claudio
    BREAST, 2019, 48 : S49 - S50
12345